不同剂量的阿柏西普对慢性中心性浆液性脉络膜视网膜病变的效果
Efficacy of different doses of aflibercept on chronic central serous chorioretinopathy
刘凤霞 1张金嵩 2关微 3刘德成3
作者信息
- 1. 郑州市第九人民医院眼科,郑州 450053
- 2. 郑州大学第一附属医院眼科,郑州 450052
- 3. 郑州市第七人民医院眼科,郑州 450016
- 折叠
摘要
目的 探讨不同剂量阿柏西普玻璃体内注射治疗慢性中心性浆液性脉络膜视网膜病变的效果与安全性.方法 回顾性病例对照研究.分析郑州市第九人民医院2019年2月至2021年2月就诊的慢性中心性浆液性脉络膜视网膜病变60例(60眼)的临床资料.所有病例按治疗方法分为两组:A组,2 mg/0.05 ml阿柏西普组玻璃体内注射组;B组,3 mg/0.075 ml阿柏西普玻璃体内注射组.每组30例(30眼).治疗后随访6个月,记录最佳矫正视力(BCVA,logMAR)、黄斑中心区视网膜厚度(CMT)、眼压及对比敏感度(CSF)的改变.结果 治疗后2周、1个月、3个月及6个月,A组 BCVA 依次为 0.43±0.36、0.36±0.28、0.28±0.27 及 0.26±0.22,B 组 BCVA 依次为 0.44±0.28、0.36±0.25、0.27±0.19 及 0.26±0.23,总体比较(F组间=5.82,P组间=0.018;F时点=26.24,P时点＜0.001;F组间×时点=0.46,P组间×时点=0.007),两组间各时点比较A组低于B组(均P＜0.05);A组CMT依次为(216.56±69.28)、(203.12±69.28)、(204.24±46.48)、(207.38±55.44)μm,B 组依次为(217.80± 71.22)、(212.32±36.47)、(212.36±36.47)、(202.43±81.26)µm,总体比较(F组间=60.22,P组间=0.002;F时点=404.66,P时点＜0.001;F组间×时点=5.32,P组间×时点=0.026),两组间各时间点比较A组低于B组(均 P＜0.05);A 组:CSF 依次为 14.31±0.69、14.59±0.02、15.68±1.22 及 17.54±0.81,B 组依次为14.28±0.89、15.42±0.24、16.62±0.72 及 18.21±0.82,总体比较(F组间=90.16,P组间＜0.001;F时点=148.65,P时点＜0.001;F组间×时点=21.22,P组间×时点＜0.001),两组间时点比较A组低于B组(均P＜0.05).结论 玻璃体内注射阿柏西普3 mg/0.075 ml较2 mg/0.05 ml阿柏西普治疗慢性中心性浆液性脉络膜视网膜病变效果更好,更有效的降低CMT,并且能更好的改善视力,安全性较好.
Abstract
Objective To investigate the efficacy and safety of different doses of aflibercept intravitreal injection on chronic central serous chorioretinopathy.Methods This was a retrospective case control study.A total of 60 eyes of 60 cases with chronic central serous chorioretinopathy treated in Zhengzhou Seventh People's Hospital from Feb.2019 to Feb.2021 were selected.They were divided into group A(intraritreal 2 mg/0.05ml aflibercept injection group)and group B(intravitreal 3 mg/0.075 ml aflibercept intravitreal injection group),with 30 eyes of 30 cases in each group.They were followed up for 6 months after treatment to record the changes of best corrected visual acuity(BCVA),central macular thickness(CMT),intraocular pressure(IOP)and contrast sensitivity function(CSF).Results At 2 weeks,1,3 and 6 months after treatment,BCVA of group A was 0.43±0.36,0.36±0.28,0.28±0.27 and 0.26±0.22,respectively.BCVA of group B was 0.44±0.28,0.36±0.25,0.27±0.19,and 0.26±0.23,respectively.The overall comparison was(Fgroups=5.82,Pgroups=0.018;Ftime=26.24,Ptime＜0.01;Fgroups×time=0.46,Pgroups×time=0.007),and BCVA in group A was lower than that in group B(all P＜0.05).At 2 weeks,1,3 and 6 months after treatment,C MT of group A was(216.56±69.28),(203.12±69.28),(204.24±46.48),and(207.38± 55.44)μm,respectively,and CMT of group B was(217.80±71.22),(212.32±36.47),(212.36±36.47),and(202.43±81.26)μm,respectively(Fgroups=60.22,Pgroups=0.002;Ftime=404.66,Ptime＜0.01;Fgroups×time=5.32,Pgroups×time=0.026),with lower results in group A than in group B(all P＜0.05).At 2 weeks,1,3 and 6 months after treatment,CSF of group A was 14.31±0.69,14.59±0.02,15.68±1.22 and 17.54±0.81,respectively.CSF of group B was 14.28±0.89,15.42±0.24,16.62±0.72,and 18.21± 0.82,respectively(Fgroups=90.16,Pgroups＜0.01;Ftime=148.65,Ptime＜0.01;Fgroups×time=21.22,Pgroups×time＜0.01),and those of group A was lower than those in the group B(all P＜0.05).Conclusion Intravitreal injection of 3mg/0.075ml of Aflibercept is more effectire than 2mg/0.05ml in treating chronic central serous chorioretinopathy,effectively reducing CMT,improring BCVA with good safety.
关键词
脉络膜视网膜病变,浆液性,中心性,慢性/阿柏西普,玻璃体内注射/剂量Key words
Chorioretinopathy,serous,central,chronic/Aflibercept,intravitreal injection/Doses引用本文复制引用
出版年
2024
NETL
NSTL
万方数据